| INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is estimated to affect 25% of the world's population and represents a spectrum of liver disease that ranges from simple steatosis (SS) to steatohepatitis (NASH), found in 30%-70% on biopsy, with or without fibrosis. 1 Approximately 41% of patients with NASH will experience progression of liver fibrosis over time, with the associated risks of developing cirrhosis, liver failure and hepatocellular carcinoma. 2 NASH is projected to become the leading indication for liver transplant in the USA by 2020. 2 However, the leading causes for morbidity and mortality in patients with NAFLD are due to atherosclerotic cardiovascular complications, with patients who have NASH or advanced fibrosis being at greater risk than those with SS. 3, 4 Various cardiovascular risk scoring systems are widely-used in clinical practice including the Framingham 5 and Qrisk2 Score. 6 These estimate the 10-year risk of atherosclerotic cardiovascular events (including acute coronary syndrome and stroke) and have been validated in large cohorts of the general population. However, patients with NAFLD may be considered of higher risk as NAFLD is associated with various markers of subclinical atherosclerosis 7, 8 and high-risk coronary disease. 9 Furthermore, the Framingham risk score does not include key features of the metabolic syndrome (including obesity and insulin resistance), which are evidently important risk factors for atherosclerotic events in those with NAFLD. 10 The standard cardiovascular screening calculations may therefore not perform as well in patients with NAFLD.
Platelet activation is a typical feature in the pathophysiology of a range of diseases, including inflammatory and vascular disorders.
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Larger platelets are metabolically and enzymatically more active than smaller platelets, with greater aggregability, and contain a greater amount of pro-thrombotic material. 12 As such, there is interest as to whether markers of platelet size and function may be a useful biomarker of activity of such disorders. Mean platelet volume (MPV) is provided with every complete blood count result and has been shown to be elevated in patients with atherothrombotic disease 13 and insulin resistance. 14 Although there are some conflicting data, 15, 16 MPV has also been shown to be elevated in people with NAFLD. [17] [18] [19] [20] [21] [22] Higher MPV levels are found in patients with more advanced fibrosis compared to earlier fibrosis, and in those with NASH compared to those without. 20, 22 We aimed to investigate whether elevated MPV is associated with an increased risk of cardiovascular events in patients with NAFLD and whether its incorporation in a cardiovascular risk score for patients with NAFLD would identify patients at higher risk for major acute cardiovascular events (MACE) compared to current standard cardiovascular risk scores.
| MATERIALS AND METHODS

| Study population
We performed a retrospective derivation (from January 2008 to July Areas under ROC curve (AUROC) with 95% confidence intervals were calculated under nonparametric (distribution free) assumption.
| Statistical analysis
Optimal cut-off values were calculated to maximise sensitivity and specificity. For each cut-off, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were reported based upon the observed prevalence of MACE within the population.
Finally, pairwise statistical comparison of AUROCs was performed using the DeLong method between NAFLD CV risk score and traditional CV risk scores.
All tests were two-sided and a P value 0.05 was considered significant. Statistical analysis was performed using SPSS © (version 24.0; SPSS Inc Chicago, IL).
| RESULTS
| Derivation group
Three hundred and sixty five patients, with a median follow-up of 36 months (18-76) were included in the derivation group: 232 (65%)
were male and 139 (39%) had hypertension. Diabetes mellitus was diagnosed in 183 (51%) patients, of whom 14% were diet controlled, patients were at moderate or high CV risk according to the Framingham score, and the mean Qrisk2 score was 12.9% ± 11.8 (Table S1 ). and on aspirin (42% vs 7%, P = 0.045) was higher in patients who experienced a MACE compared to those who did not. The Qrisk2 score was higher in patients who experienced a MACE (22.5 vs 11.5, P < 0.001) but not the Framingham score (Table 1 ).
231 (65%) patients in the derivation group underwent a liver biopsy, 24 (10%) of whom experienced a MACE. The presence of advanced fibrosis (stage 3-4) and CPA > 5% were higher in patients who experienced MACE compared to those that did not (71% vs 43%, P = 0.023 and 41% vs 28%, P = 0.047). Fat % and steatosis grade, lobular inflammation and ballooning score, as well as the presence of definite or probable NASH, were not significantly different between the subgroups (Table 2 ).
| NAFLD Cardiovascular-risk score
On univariate analysis, age, presence of diabetes mellitus, advanced fibrosis (F3-F4), CPA > 5%, liver stiffness and MPV were associated with a 1-year risk of MACE. However, after multivariate analysis, only age (HR 1.12, 1.01-1.23, P = 0.01), presence of diabetes (HR 1.9, 1.1-2.7, P = 0.002) and MPV (HR 2.9, 1-3.7, P = 0.02) remained independently associated with 1-year risk of MACE (Table 3) .
Using binary logistic regression, a formula was generated to predict acute CV events within one year. In this formula, termed the NAFLD CV-risk score, the weight of each variable was assigned A free online tool to calculate the formula is available via the following link: https://ld-eye.com/index.php?r=site/CVDRiskScore.
In the derivation cohort, the NAFLD CV-risk score ranged from −7.1 to 3.6. The mean NAFLD CV risk score was higher in the group with MACE compared to those without MACE, −0.8 ± 1.4 and −2.9 ± 1.5 respectively (P = 0.003). The overall Brier score was 0.08, indicating that the prediction of the formula was accurate. Moreover, the Hosmer-Lemeshow test was 0.99, indicating that the derived model fits well.
AUROCs for the prediction of MACE in the derivation cohort were 0.84 (P = 0.001, 95% CI = 0.78-0.91) for NAFLD CV-risk score and 0.83 (P = 0.001, 95% CI = 0.77-0.89) for MPV alone (Figure 1) . A cutoff of NAFLD CV risk score of −3.98 gave a sensitivity 97%, specificity 27%, PPV 16% and NPV 99%. A cut-off of MPV >10.05 gave a sensitivity 97%, specificity 59%, PPV 24% and NPV 97% (Table 4 ). patients in the validation group underwent liver biopsy, of whom 7
| Validation of NAFLD CV score and MPV
(8%) experienced a MACE. There were no significant differences between the derivation and validation groups with regards to clinical variables. In the derivation group, a higher proportion of biopsies had mild fibrosis (F1-2) (44% vs 26%, P = 0.004) but a lower proportion had mild steatosis (29% vs 44%, P = 0.03) than the validation group biopsies (Tables S1 and S2 ).
In the validation cohort, NAFLD CV risk score values ranged from (Table 4) .
| Comparison of NAFLD CV score and MPV vs traditional scores
The clinical, biochemical and histological differences between patients who experienced a MACE and those that did not for the whole study cohort are presented in Tables S3 and S4 . In the whole study population, the NAFLD CV-risk score ranged from −8.4 to 3.6. The mean NAFLD CV risk score was higher in the group with MACE compared to those without MACE, −0.97 ± 1.6 and −2.8 ± 1.5, respectively (P = 0.002). AUROCs for the prediction of MACE were 0.83 (P = 0.001, 95% CI=0.77- 
| DISCUSSION
We have demonstrated that the prevalence of MACE in our cohort of NAFLD patients is 12%, which is double the age standardised prevalence of MACE in the UK. 29 We have presented a prospectively validated cardiovascular risk score algorithm in NAFLD with a result of more than −3.98 predicting a 16%-27% 1-year chance of suffering a MACE and a result lower than −3.98 giving a 97%-99% accurate negative predictive value. Finally, we have highlighted the clinical significance of a raised MPV in this patient cohort.
Our study has several strengths. Firstly, our patient cohort was well selected for NAFLD, as all patients had negative non-invasive were not over-estimated. A limitation of our study is that all patients were recruited from a tertiary level specialist NAFLD clinic and so this may lead to a selection bias towards a more high-risk population. Indeed, 50% of our biopsied patients had advanced fibrosis, much higher than would be seen in general secondary or primary care clinics. Nonetheless, our data re-emphasise the importance of assessing cardiovascular risk for patients with NAFLD within a specialist clinic and further validation within a secondary or primary care setting is warranted. A further limitation is that we only quantified alcohol intake of included patients using clinical assessment (rather than a validated questionnaire of alcohol intake), and it is therefore possible that a small proportion of included patients had alcohol use as a contributory factor to their liver disease.
In the general population, the risk of atherosclerotic cardiovascular disease is estimated using one of the established scoring systems, such T as the Qrisk2 or Framingham, to guide primary prevention with pharmacological therapy, 30 whilst interventional therapy is not undertaken routinely for primary prophylaxis. A previous study demonstrated that the Framingham score had utility in predicting coronary heart disease in NAFLD patients, 31 but assessment for other MACE was not performed. MELD-Na has also been shown to have a potential role in predicting MACE in NAFLD patients, but FIB-4 (rather than histology) was used to assess fibrosis stage in this study, limiting interpretability. 32 There has also been the recent demonstration that the atherogenic index of plasma (AIP; an established risk factor for cardiovascular disease) in those with abnormal metabolic profiles compared to those with normal profiles, which is likely to also be of relevance to NAFLD. 33 Our novel algorithm outperforms the established scoring systems, however, it is accepted that the established scores were developed to identify a 10% risk of MACE at 10 years rather than 1-year risk. 31 Nevertheless, given the high prevalence of MACE in NAFLD, our data would certainly support the importance of assessing 1-year risk using the NAFLD CV Risk Score and ensuring that high risk patients are on primary prophylaxis.
Interestingly, a significant proportion of our patients who suffered from a MACE were not taking statins, anti-hypertensive medications or aspirin. It should also be noted that a higher proportion of patients who were on these medications still experienced a MACE compared to those that were not on these medications. Therefore, it could be argued that these patients would benefit from enhanced cardiovascular risk assessment and referral to a cardiologist.
Our data are consistent with those previously published with regards to the major risk factors associated with the development of MACE, namely age, heavy smoking, and the presence of hypertension or diabetes. 34 In contrast with published data that suggests the degree of steatosis, as defined by ultrasound criteria, is associated with an increased risk of cardiovascular events, [35] [36] [37] we did not find any association between the severity of histological steatosis and cardiovascular risk. Consistent with Ekstedt et al and others 4, 38 we found that only advanced fibrosis (defined histologically or by transient elastography) was associated with an increased cardiovascular risk but not the severity of NASH (as defined by NAS score or its constituent components). In addition, consistent with previous data, 39 transaminases were not associated with an elevated risk of MACE. Given the widespread availability of MPV as part of the standard full blood count, this single variable could be used as a simple and cheap initial screening tool by primary and secondary care physicians.
In the general population, raised MPV levels (but not platelet number) are associated with coronary artery disease events, including acute MI, as well increased rates of restenosis after MI. 40, 41 The risk of stroke also appears to increase as MPV increases, as does an increased likelihood of larger volumes of cerebral damage, 42, 43 together with the risk of early death in the early post-stroke period. 40 Raised MPV also has a strong and independent association with venous thromboembolic disease, even in the absence of trauma, surgery, immobilisation or malignancy. 44 Furthermore, elevated MPV has also been showed to be associated with higher overall mortality within a population of patients requiring haemodialysis, a group who are at particularly high risk of atherosclerotic cardiovascular events. 45 A clear future direction of interest for this work will be to establish greater mechanistic understanding of the association between the level of MPV and NAFLD's stage and cardiovascular complications, which may shed fresh insight into the pathophysiology of the condition. There have been several proposed mechanisms to explain the link between raised MPV level and cardiovascular events, in particular that larger platelets contain a higher density of prothrombotic material, encouraging the release of substances that amplify platelet activation, platelet adhesion and vascular neointimal proliferation, such as thromboxane A2. 46 Larger platelets also demonstrate greater aggregability 47, 48 ; furthermore, they also express a greater density of glycoprotein Ib and IIb/IIIa adhesion receptors, and display more reticulation, both being factors associated with a worse response to anti-platelet therapy. 49, 50 There are likely to be several factors contributing to the relationship between elevated MPV levels and the presence of advanced fibrosis in NAFLD. Firstly, insulin resistance may have a direct effect on platelet function per se: MPV levels are higher in non-obese, normoglycaemic people with insulin resistance than matched people without, 14 with insulin resistance causing reduced platelet sensitivity to the anti-aggregating effects of insulin. 51, 52 In addition, there appears to be a relationship between inflammation, platelet activity and hepatic fibrosis. Specifically, cytokines are key mediators of hepatic inflammation, and cytokines derived from the adipose tissue appear to play a key role in the progression of NAFLD. 53 NAFLD is associated with an increase in inflammatory cytokines (including IL-1, IL-6 and TNF-α), with cytokine plasma levels in NAFLD related to hepatic fat content, the degree of inflammation, and the extent of hepatic fibrosis. 53 It has been previously suggested that adipose and a dysfunctioning epithelium may affect the bone marrow to produce larger platelets via cytokine-driven mechanisms, with the characteristic cytokine profile found in people with NAFLD therefore affecting platelet size in people with the condition. 54 Given the apparent association between platelet activity, inflammation and hepatic fibrosis, a limitation of our study is that inflammatory markers (including C-reactive protein and ESR) were not available for all patients, so could not be considered in the development of our algorithm. Another future area of interest would be the exploration as to whether integration of such inflammatory markers into the NAFLD CV risk score may be of additional utility for the prediction of MACE in patients with NAFLD.
In summary, patients with NAFLD and a NAFLD CV score of more than −3.98 or a MPV greater than 10.05 are at a high risk of experiencing a MACE within 12 months. 1-year cardiovascular risk is related to fibrosis stage rather than steatohepatitis. Physicians should, therefore, ensure that these patients are on appropriate primary prevention strategies and strongly consider referral for formal cardiovascular assessment. Understanding the pathophysiological mechanisms that underlie the association between an elevated MPV and cardiovascular risk may provide a novel target for drug development.
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